Article information
Full text is only aviable in PDF
REFERENCES
[1]
WH Inman, AM Adelstein.
Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols.
Lancet, 2 (1969), pp. 279-285
[2]
J Crane, N Perace, A Flatt, et al.
Prescribed fenoterol and death from asthma in New Zealand, 1981–1983: a case-control study.
Lancet, 1 (1989), pp. 917-922
[3]
N Pearce, J Grainger, M Atkinson, et al.
Case control study of prescribed fenoterol and death from asthma in New Zealand, 1977–1981.
Thorax, 45 (1990), pp. 170-175
[4]
J Grainger, K Woodman, N Pearce, et al.
Prescribed fenoterol and death from asthma in New Zealand 1981–1987: a further case-control study.
Thorax, 46 (1991), pp. 105-111
[5]
WO Spitzer, S Suissa, P Ernst, et al.
The use of beta-agonists and the risk of death and near death from asthma.
N Engl J Med, 326 (1992), pp. 501-506
[6]
W Castle, R Fuller, J Hall, J Palmer.
Serevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
BMJ, 306 (1993), pp. 1034-1037
[7]
J Hasford, JC Virchow.
Excess mortality in patients with asthma on long-acting b-agonists.
Eur Respir J, 28 (2006), pp. 900-902
[8]
HS Nelson, ST Weiss, ER Bleecker, et al.
The salmeterol multicenter asthma research trial.
Chest, 129 (2006), pp. 15-26
[9]
J Wolfe, C Laforce, B Friedman, et al.
Formoterol, 24 µg bid, and serious asthma exacerbations. Similar rates compared with formoterol, 12 µg bid with and without extra doses taken on demand, and placebo.
Chest, 129 (2006), pp. 27-38
[10]
G Bensch, R Lapidus, B Levine, et al.
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Ann Allergy Asthma Immunol, 86 (2001), pp. 19-27
[11]
G Bensch, W Berger, M Blokhin, et al.
One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
Ann Allergy Asthma Immunol, 89 (2002), pp. 180-190
[12]
SR Salpeter, NS Buckley, TM Ormiston, EE Salpeter.
Meta-analysis: effect of long-acting b-agonists on severe asthma exacerbations and asthma related deaths.
Ann Intern Med, 144 (2006), pp. 904-912
[13]
EM Kallergis, EG Manios, EM Kanoupakis, et al.
Acute electrophysiologic effects of inhaled salbutamol in humans.
Chest, 127 (2005), pp. 2057-2063
[14]
SR Salpeter, TM Ormission, EE Salpeter.
Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis.
Chest, 125 (2004), pp. 2309-2321
[15]
M Cazzola, MG Matera, CF Donner.
Inhaled b2-adrenoreceptor agonists. Cardiovascular safety in patients with obstructive lung disease.
Drugs, 66 (2005), pp. 1595-1610
[16]
C Domingo, M Navarro, R Comet, et al.
Effect of early versus late intervention with inhaled corticosteroid in bronchial asthma: pulmonary function benefits and side-effects at the end of a threemonth follow-up.
Eur Respir J, 12 (1998), pp. 81
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
